Insights from 2023 ESMO Annual Meeting
ESMO 2023 Insights: "AIM-HN Study Evaluating Tipifarnib in mHRAS, Recurrent/Metastatic HNSCC"
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Alan Ho
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Alan Ho
Comments 0
Login to view comments.
Click here to Login
